Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity

NCT01271751 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherogenic Dyslipidaemia
Abdominal Obesity

Interventions

DRUG: GFT505 80mg
DRUG: Placebo

Sponsor

Genfit